Overview
Lobbying Costs
9,999€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
1.25 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Anticancer Fund (ACF)
EU Transparency Register
404359320127-95 First registered on 30 Dec 2015
Goals / Remit
The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.
The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by:
- Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatmentsMain EU files targeted
Main EU legislative proposals or policies targeted:
Europe’s Beating Cancer Plan
Horizon and the Cancer Mission
New Pharmaceutical Strategy
Special Committee on Cancer (BECA)
MAC Group (Members of Parliament Against Cancer)
Cancer related policies
Research and clinical trials
Market authorisation for innovative medicinesAddress
Head Office
Boechoutlaan
221
Strombeek-Bever 1853
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 75% 1 25% 2 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
https://www.europeancancer.org/
https://epha.org/
https://www.esmo.org/
https://www.asco.org/
https://www.icrpartnership.org/Member organisations
European Cancer Organisation
European Public Health Alliance
European Society for Medical Oncology
American Society of Clinical Oncology
International Cancer Research Partnership -
Financial Data
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
9,999€
Other financial info
In the year 2020, we did not participate in any activities covered by the Register. This registration is aiming at a dialogue with the EC to change a particular policy so no direct costs involved.
ACF is fully privately sponsored. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
1. Public health related guidelines
2. Member of the Repurposing Observatory Group (RepOG)
3. Targeted EU Contact Program on cancer related policy:
- Manifesto emphasising on the potential of repurposing drugs in oncology
- Individual meetings with MEPs, Commissioners and Committee Members
- Recommendations, feedback and reflections on how to strengthen Europe in the fight against cancer
- Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemicOther activities
Participation: Virtual Townhall Meeting for the Europe's Beating Cancer Plan (10 September 2020)
Panelist invited by Olga Solomon: Pharmaceutical Strategy for Europe - Building a comprehensive pharmaceutical policy to address today’s challenges and tomorrow’s realities - DG SANTE Session - European Health Forum Gastein 2020 (1 October 2020)
Meetings
Meetings
None declared